Literature DB >> 16582619

Identification of novel ARF binding proteins by two-hybrid screening.

Van Tompkins1, Jussara Hagen, Valerie P Zediak, Dawn E Quelle.   

Abstract

The ARF tumor suppressor protects us against cancer through protein-protein interactions in partially defined p53-dependent and p53-independent pathways. We performed a two-hybrid screen using ARF as bait and present the identification of several new ARF partners that may regulate its growth inhibitory signaling. The potential physiological roles of these novel ARF binding proteins in regulating ARF signaling are discussed.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16582619

Source DB:  PubMed          Journal:  Cell Cycle        ISSN： 1551-4005            Impact factor:   4.534


  25 in total

1.  Generation and characterization of monoclonal antibodies to NIAM: a nuclear interactor of ARF and Mdm2.

Authors:  Jussara Hagen; Van Tompkins; Amel Dudakovic; Jamie A Weydert; Dawn E Quelle
Journal:  Hybridoma (Larchmt)       Date:  2008-06

2.  A novel prognostic marker of non-small cell lung cancer: chromosome 9 open reading frame 86 (C9orf86).

Authors:  Katsuhiro Yoshimura; Murat Osman; Yusuke Inoue; Takafumi Suda; Haruhiko Sugimura
Journal:  J Thorac Dis       Date:  2016-09       Impact factor: 2.895

3.  RABL6A promotes G1-S phase progression and pancreatic neuroendocrine tumor cell proliferation in an Rb1-dependent manner.

Authors:  Jussara Hagen; Viviane P Muniz; Kelly C Falls; Sara M Reed; Agshin F Taghiyev; Frederick W Quelle; Francoise A Gourronc; Aloysius J Klingelhutz; Heather J Major; Ryan W Askeland; Scott K Sherman; Thomas M O'Dorisio; Andrew M Bellizzi; James R Howe; Benjamin W Darbro; Dawn E Quelle
Journal:  Cancer Res       Date:  2014-10-01       Impact factor: 12.701

4.  RABL6A inhibits tumor-suppressive PP2A/AKT signaling to drive pancreatic neuroendocrine tumor growth.

Authors:  Shaikamjad Umesalma; Courtney A Kaemmer; Jordan L Kohlmeyer; Blake Letney; Angela M Schab; Jacqueline A Reilly; Ryan M Sheehy; Jussara Hagen; Nitija Tiwari; Fenghuang Zhan; Mariah R Leidinger; Thomas M O'Dorisio; Joseph Dillon; Ronald A Merrill; David K Meyerholz; Abbey L Perl; Bart J Brown; Terry A Braun; Aaron T Scott; Timothy Ginader; Agshin F Taghiyev; Gideon K Zamba; James R Howe; Stefan Strack; Andrew M Bellizzi; Goutham Narla; Benjamin W Darbro; Frederick W Quelle; Dawn E Quelle
Journal:  J Clin Invest       Date:  2019-03-04       Impact factor: 14.808

Review 5.  Therapeutic targets in the ARF tumor suppressor pathway.

Authors:  Anthony J Saporita; Leonard B Maggi; Anthony J Apicelli; Jason D Weber
Journal:  Curr Med Chem       Date:  2007       Impact factor: 4.530

6.  RABL6A Promotes Oxaliplatin Resistance in Tumor Cells and Is a New Marker of Survival for Resected Pancreatic Ductal Adenocarcinoma Patients.

Authors:  Viviane P Muniz; Ryan W Askeland; Xuefeng Zhang; Sara M Reed; Van S Tompkins; Jussara Hagen; Bradley D McDowell; Anna Button; Brian J Smith; Jamie A Weydert; James J Mezhir; Dawn E Quelle
Journal:  Genes Cancer       Date:  2013-07

7.  Nuclear interactor of ARF and Mdm2 regulates multiple pathways to activate p53.

Authors:  Sara M Reed; Jussara Hagen; Van S Tompkins; Katie Thies; Frederick W Quelle; Dawn E Quelle
Journal:  Cell Cycle       Date:  2014-02-19       Impact factor: 4.534

8.  RABL6A Is an Essential Driver of MPNSTs that Negatively Regulates the RB1 Pathway and Sensitizes Tumor Cells to CDK4/6 Inhibitors.

Authors:  Jordan L Kohlmeyer; Courtney A Kaemmer; Casey Pulliam; Chandra K Maharjan; Allison Moreno Samayoa; Heather J Major; Kendall E Cornick; Vickie Knepper-Adrian; Rajesh Khanna; Jessica C Sieren; Mariah R Leidinger; David K Meyerholz; K D Zamba; Jill M Weimer; Rebecca D Dodd; Benjamin W Darbro; Munir R Tanas; Dawn E Quelle
Journal:  Clin Cancer Res       Date:  2020-02-21       Impact factor: 12.531

9.  Zinc finger protein 91 positively regulates the production of IL-1β in macrophages by activation of MAPKs and non-canonical caspase-8 inflammasome.

Authors:  Chunliu Mi; Zhe Wang; Ming Yue Li; Zhi Hong Zhang; Juan Ma; Xuejun Jin
Journal:  Br J Pharmacol       Date:  2018-10-15       Impact factor: 8.739

10.  Residues in the alternative reading frame tumor suppressor that influence its stability and p53-independent activities.

Authors:  Anne di Tommaso; Jussara Hagen; Van Tompkins; Viviane Muniz; Amel Dudakovic; Alain Kitzis; Veronique Ladeveze; Dawn E Quelle
Journal:  Exp Cell Res       Date:  2009-01-27       Impact factor: 3.905
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.